Emergent Health Corp (EMGE)

[powerbattles]

$EMGE Insight into the company's pending acquisition, merger, and the upcoming Spin-off of PHARMAZU IPO. This IPO will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION for EMGE shareholders.

Anyone who has traded 000's for a while knows that it's super rare to find a company poised for massive growth. Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%". This unique opportunity extends to the company's small share structure, boasting a market capitalization of only 490k. As of 01/30/2024, the outstanding shares (o/s) stand at 426 million, with 134 million restricted 292 unrestricted, and merely 220 million held at DTC. There has been no toxic dilution, as both the float and outstanding shares have remained unchanged for the past 9 months. This combination of impressive revenue potential, a compact share structure, and a lack of dilution positions this company as a compelling prospect for those seeking a promising investment opportunity and a potential bull run in 2024.

It's Official: Former L'Oreal President Jim Morrison Is Now Emergent Health Corporations. He's the CEO and transitioning to the role of Chairman of the Board at Emergent. Morrison has had a legendary career including numerous leadership positions in the personal care industry, most notably as President of L'Oréal. While at L'Oréal, Morrison oversaw growth that averaged more than 20% year-over-year. He engineered the acquisitions of Redken and Matrix and led the company during a period of unprecedented growth during his tenure.

L'Oréal S.A. is a French personal care company headquartered in Clichy, Hauts-de-Seine, with a registered office in Paris. It is the world's largest cosmetics company As of January 24, 2024, the stock price of L’Oreal SA is 429.0 EUR. The company has a market capitalization of 228.06 billion USD https://www.lorealparisusa.com/ https://www.loreal.com/en/

Emergent the company has the following subsidiaries
https://emergenthealthcompany.com/

1 - Emergent Medical Foods, Inc., a Wyoming corporation incorporated on April 4, 2019,

2 - Emergent OTC Products, Inc., a Wyoming corporation incorporated on August 1, 2019,

3 - PharmaZu, Inc., a Florida corporation incorporated on December 28, 2021.

4 - The Company acquired the assets and certain liabilities of Regen Biowellness, Inc. on August 2, 2022,

5 - Evolutionary Biologics, Inc., a Delaware corporation, acquired on August 15, 2022

Recent Events
MERGER Agreement and SPIN-OFF of PHARMAZU

Apollo Merger Agreement. We have entered into a Plan and Agreement of Merger (the Merger Agreement) with Apollo Biowellness, Inc., a Delaware corporation (Apollo). Our management has determined that there is no impediment to our closing the Merger Agreement. Previously the Company had announced its intention to sell Evolutionary Biologics, Inc., one of its subsidiaries, to Apollo. That transaction has been abandoned, and the Company instead chose to acquire and merge with Apollo

"As part of the roll-up being conducted by Boustead and Apollo Biowellness, effective June 1, 2023, Mr. Morrison will take over as President/CEO of Apollo Biowellness." From my point of view, Morrison taking over as President/CEO of Apollo Biowellness is a positive move. Transitioning to the role of Chairman of the Board at Emergent, his dual involvement with both companies positions him perfectly to coordinate with Boustead moving forward.

HUGE MERGER WITH APOLLO BIOWELLNESS INC.

https://apollobiowellness.com/

The New APOLLO BioWellness Inc.

(Formerly EMERGENT HEALTH COMPANY)

The Future of Regenerative Health

The New APOLLO BioWellness Inc. owns FIVE SUBSIDIARIES:

https://evolutionarybiologics.com/

https://integrativepracticesolutions.com/

https://apollobiowellness.com/wholistic/

https://juventix.com/

https://apollobiowellness.com/maximus/



Upcoming SPIN-OFF PharmaZu IPO that will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION to the Emergent Shareholders.

Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it has executed a Term Sheet for a firm committed underwriting with a nationally recognized investment banking firm for $10,000,000 with respect to planned corporate financing transactions, including the private placement of securities (“pre-IPO Financings”) and the planned $10 million initial public offering of Emergent subsidiary PharmaZu common stock (“IPO”) that will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION to Emergent shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on a national exchange, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. Subsequently, Emergent plans to distribute to its shareholders, pro rata, the shares of PharmaZu as a dividend, when a record date is set.

MERGER IT'S OFFICIAL: Filing Name Changed Emergent Health Corp To Apollo Biowellness, Inc. According to the filings stated below, the R/S is no longer in effect after September 30, 2023.



ACQUISITION

In December 2023, we entered into a non-binding letter of intent (the “LOI”)
with Accredited Solutions, Inc., a publicly-traded company (symbol: ASII). The LOI
contemplates a sale of certain of our assets, including Evolutionary Biologics, Inc., Nanostehic,
Inc., Nanogistics, Inc., and the brand Maximus Men's Health to ASII, in exchange for a new
class of preferred stock of ASII that would equate to an equity ownership of not less than 80% of
ASII. The corporate structure of the proposed transaction and other relevant terms have not yet
been finalized. The LOI contemplates that the transaction would close early in the first quarter of
2024. However, there is no guarantee that such will be the case

This acquisition is highly favorable. We sell them the asset, and in return, we gain not less than 80% full control of their company. Just think about it—we haven't sold or lost anything in the process. That is the power of negotiation.

I think this news is well worth checking out.
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics.
https://www.globenewswire.com/en/news-release/2023/09/12/2741711/0/en/BioRestorative-Therapies-Enters-into-Supply-Agreement-with-Evolutionary-Biologics.html

Jim Morrison, Chief Executive Officer of Evolutionary Biologics, a division of Emergent Health Corp, (EMGE) stated “we are very excited to be working with Biorestorative Therapies. They are a world class manufacturer of biological products, and operate a state-of-the-art Laboratory and manufacturing facility. This partnership will undoubtedly provide Evolutionary Biologics with a competitive advantage in the large and fast-growing biologics cosmetic marketplace".

Keep in mind “BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) "Founded in 2020 by former L'Oreal President, Jim Morrison. Evolutionary Biologics is a supplier of cosmetic-focused biologics for plastic surgeons, dermatologists and medical spas across the United States.

Mr. Morrison is a legend in the personal care industry, most notably as President of L'Oréal. While at L'Oréal, Morrison oversaw growth that averaged more than 20% year-over-year. He engineered the acquisitions of Redken and Matrix and led the company during a period of unprecedented growth during his tenure. He is considered one of the top brand strategists in the personal care space. Morrison has had a long history of working with celebrities in the beauty space, such as Britney Spears, Kimora Lee Simmons, Flo Rida, Katharine McPhee, Christie Brinkley, Rob Lowe, Kylie Jenner, and others.
Business Week Magazine previously wrote: "Over the last two decades, Mr. Morrison has had a profound impact on the American Beauty Industry. In the industry's history, no other executive has had the level of financial responsibility or breadth of organizational experience as Jim. His devotion to, and success within the American Beauty Industry is unmatched."

Unlock all the news:
https://www.marketscreener.com/quote/stock/EMERGENT-HEALTH-CORP-120790864/news/

This stock remains undiscovered by the masses. Additionally, very few are aware that the reverse split (r/s) is no longer in effect after September 30, 2023. I see extremely great value in the current situation. The merger is in progress, as of now, the name change has occurred, but the merger's official closure has not been announced. Typically, mergers and IPO spin-offs trigger a substantial increase in share prices. In this case, the merger will lead to the spin-off of Pharmazu, and shareholders will receive dividends in the form of an IPO. It's rare to encounter an opportunity to capture both a merger and an IPO. As per the news, the initial public offering of Emergent subsidiary PharmaZu common stock ("IPO") is set to be listed on NASDAQ or NYSE/AMEX, with no dilution for Emergent shareholders.

This is the end of part one. For part two I will offer an in-depth analysis of the management team, highlighting both their strengths and weaknesses. In part three, I'll uncover essential aspects like company revenue, services, patents, products, and market share. Stay tuned for a comprehensive examination that goes beyond the surface, covering every facet of this investment opportunity.

All of my posts reflect my personal opinions only. Please refrain from making any buying or selling decisions regarding securities based on my posts. I am not a financial advisor; you are the only one responsible for your trades and investment decisions! I do not receive any form of compensation, whether in cash or shares, from any company or third party mentioned in my posts.